bioMérieux SA

bioMérieux SA is a family-owned French company and a world leader in the field of in vitro diagnostics, founded in 1963 by the Mérieux family. It pioneers, develops, and produces high-quality diagnostic solutions to improve public health worldwide, with a core purpose of making the world a healthier place through innovation in pathogen detection and identification. The company focuses on combating major threats like infectious diseases, antimicrobial resistance, sepsis, and ultra-resistant bacteria, accelerated by climate change and globalization. Its offerings support clinicians in enhancing patient care and help industries prevent contamination in food safety, pharmaceutical quality control, and beyond. Notable advancements include rapid automated flow cytometry via the acquisition of Accellix for cell and gene therapy, and BIOFIRE® SPOTFIRE® panels for respiratory and sore throat diagnostics in urgent care. bioMérieux sustains a robust business model for ongoing innovation, implements environmentally responsible actions, fosters ethical dialogue in the healthcare ecosystem, and builds long-term community partnerships, upholding values of respect, accountability, transparency, and sharing.